Table 2.
Pooled prevalence of sarcopenia according to different subgroups.
| Subgroups | Studies (n) | Participants (n) | Prevalence, % (95% CI) | I 2 | P-value for χ2 | P-value for interaction |
|---|---|---|---|---|---|---|
| Overall | 8 | 8,856 | 22.1 (18.7–25.6) | 94.7% | <0.001 | NA |
| Diagnostic criteria | ||||||
| AWGS | 2 | 1,145 | 18.5 (14.3–22.7) | 70.7% | 0.065 | 0.002 |
| EWGSOP | 6 | 7,946 | 23.6 (18.9–28.3) | 96.3% | <0.001 | |
| FNIH | 1 | 644 | 16.5 (13.6–19.3) | NA | NA | |
| SARC-F | 1 | 409 | 25.2 (21.0–29.4) | NA | NA | |
| Sex | ||||||
| Men | 4 | 1,880 | 23.2 (21.3–25.1) | 0.0% | 0.298 | 0.023 |
| Women | 4 | 1,991 | 15.5 (9.2–21.9) | 92.1% | <0.001 | |
| Study period | ||||||
| <2015 | 4 | 7,391 | 22.9 (18.0–27.8) | 97.1% | <0.001 | 0.504 |
| ≥2015 | 4 | 1,465 | 20.7 (16.5–24.9) | 75.1% | 0.007 | |
| Study quality | ||||||
| High | 6 | 8,142 | 22.6 (18.8–26.4) | 95.5% | <0.001 | 0.649 |
| Moderate | 2 | 714 | 20.1 (10.2–30.0) | 91.4% | 0.001 | |
| Study location | ||||||
| Bushehr | 1 | 2,426 | 27.4 (19.6–35.2) | NA | NA | 0.457 |
| Ravansar | 1 | 4,021 | 22.0 (20.7–23.3) | NA | NA | |
| Shiraz | 1 | 501 | 20.8 (17.2–24.3) | NA | NA | |
| Tehran | 5 | 1,908 | 20.7 (16.1–25.3) | 90.8% | <0.001 | |
| Sample size, n | ||||||
| <500 | 4 | 1,264 | 20.0 (15.5–24.5) | 75.7% | 0.005 | 0.313 |
| 500–1,000 | 2 | 1,145 | 21.4 (14.2–28.6) | 95.1% | <0.001 | |
| >1,000 | 2 | 6,447 | 25.6 (19.9–31.3) | 97.4% | <0.001 | |
CI, confidence interval; NA, not applicable; AWGS, Asian Working Group for Sarcopenia; EWGSOP, European Working Group on Sarcopenia in Older People; FNIH, Foundation for the National Institutes of Health; SARC-F, Strength, Assistance walking, Rising from a chair, Climbing stairs, Falls.